Focus: MapLight Therapeutics is a rare disease biotech focused on optogenetics-based therapeutics for neuropsychiatric and neurodegenerative conditions. The company is in Series C+ stage with a lean operational footprint headquartered in Burlington, MA.
Profile data last refreshed 12h ago · AI intelligence enriched 3w ago
Stable — net -2 jobs in 30d
2 added, 4 removed. Backfill posture.
Compelling scientific opportunity for early-career biotech professionals seeking optogenetics exposure and equity upside, but capital and clinical execution risk require tolerance for pre-commercial volatility.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for MapLight Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from MapLight Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Form 4 MapLight Therapeutics Inc: Erin Pennock Foff (Chief Medical Officer) For: 15 October By Investing.com - Investing.com South Africa
Form 4 MapLight Therapeutics Inc: Erin Pennock Foff (Chief Medical Officer) For: 15 October By Investing.com Investing.com South Africa
Form 4 MapLight Therapeutics Inc: Anatol Kreitzer (Chief Discovery Officer) For: 15 October By Investing.com - Investing.com South Africa
Form 4 MapLight Therapeutics Inc: Anatol Kreitzer (Chief Discovery Officer) For: 15 October By Investing.com Investing.com South Africa
Form 4 MapLight Therapeutics Inc: James Woodruff Lillie (Chief Scientific Officer) For: 15 October - Investing.com Nigeria
Form 4 MapLight Therapeutics Inc: James Woodruff Lillie (Chief Scientific Officer) For: 15 October Investing.com Nigeria
Form 4 MapLight Therapeutics Inc: Kristopher Hanson (General Counsel) For: 15 October - Investing.com Canada
Form 4 MapLight Therapeutics Inc: Kristopher Hanson (General Counsel) For: 15 October Investing.com Canada
MapLight Therapeutics, Inc. (MPLT) Stock Price, News, Quote & History - Yahoo! Finance Canada
MapLight Therapeutics, Inc. (MPLT) Stock Price, News, Quote & History Yahoo! Finance Canada
Form 4 MapLight Therapeutics Inc: Anatol Kreitzer (Chief Discovery Officer) For: 15 October - Investing.com Nigeria
Form 4 MapLight Therapeutics Inc: Anatol Kreitzer (Chief Discovery Officer) For: 15 October Investing.com Nigeria
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Preclinical efficacy of the muscarinic agonist ML-007 in psychosis models depends on both M(1) and M(4) receptors.
A novel, experimental design to assess rapid antidepressant action: Results from a phase 1b randomized trial of NV-5138.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo